Objective: Posttraumatic stress disorder (PTSD) increases cardiovascular disease and cardiovascular mortality risk. Neither the prospective relationship of PTSD to incident hypertension risk nor the effect of PTSD treatment on hypertension risk has been established. Methods: Data from a nationally representative sample of 194,319 veterans were drawn from the Veterans Administration (VA) roster of United States service men and women. This included veterans whose end of last deployment was from September 2001 to July 2010 and whose first VA medical visit was from October 1, 2001 to January 1, 2009. Incident hypertension was modeled as 3 events: (1) a new diagnosis of hypertension and/or (2) a new prescription for antihypertensive medication, and/or (3) a clinic blood pressure reading in the hypertensive range (≥140/90 mm Hg, systolic/diastolic). Posttraumatic stress disorder diagnosis was the main predictor. Posttraumatic stress disorder treatment was defined as (1) at least 8 individual psychotherapy sessions of 50 minutes or longer during any consecutive 6 months and/or (2) a prescription for selective serotonin reuptake inhibitor medication.
INTRODUCTION P
osttraumatic stress disorder (PTSD), a disabling condition that develops consequent to trauma, is defined in part by hyperarousal, avoidance, and re-experience of trauma (1) . It is the most commonly diagnosed mental health disorder in veterans with combat exposure (2, 3) , with a prevalence in men and women of more than 20% (2) , and a significant impact on quality of life and physical health domains (2, 4, 5) . Posttraumatic stress disorder is often accompanied by elevated resting heart rate (HR) and blood pressure (BP), an exaggerated HR and BP response to stressful stimuli under laboratory conditions (6) , and alterations of autonomic (7) (8) (9) and hypothalamic-pituitary-adrenal (HPA)-axis (10) regulation, processes that can contribute to eventual cardiovascular system damage (11) . Wide-ranging cross-sectional and prospective studies (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) of individuals with a diagnosis of PTSD and those with elevated PTSD symptoms not sufficient to meet diagnostic criteria reveal a higher prevalence of cardiovascular disease (CVD) and, as we reported in a recent meta-analysis (26) , greater risk for early CVD events or CVD-specific mortality that is independent of traditional risk factors . With this evidence, researchers are stating that it is time to develop and test interventions targeted to reduction of CVD risk associated with PTSD (27) .
Posttraumatic stress disorder has also been linked to hypertension, a major risk factor for CVD and stroke, which together impose a more than $69 billion annual financial burden in the United States. In a small convenience sample of US military veterans (28) , the resting systolic/diastolic BP were 11/9 mm Hg higher among those with versus without PTSD. The National Comorbidity Study reported in multivariate analyses a 2-fold greater prevalence of hypertension among those with versus without PTSD (15) , with similar cross-sectional findings in a registry of more than 300,000 veterans (29) . A relatively small prospective study of veterans who sought primary care treatment found that PTSD increased the odds of a range of medical and mental health conditions over a median of 4.5 years, including a hypertension diagnosis by 38% (30) . Whereas these studies provide a signal that PTSD is independently related to hypertension risk, with the exception of one small regional study, the analyses are all cross-sectional. Furthermore, these findings do not provide any information regarding the effect that PTSD treatment has on the relationship between PTSD and hypertension, a critical question if efforts to reduce hypertension and CVD risk associated with PTSD are to be mounted.
In the current study, we used data from a large national registry of almost 300,000 veterans deployed from September 11, 2001 to January 1, 2009, to investigate the prospective relationship of PTSD to incident hypertension. We furthermore tested whether treatment for PTSD was associated with attenuation of the effect of PTSD on incident hypertension risk.
METHODS

Data Sources and Study Population
The sample was selected from the list of Veterans obtained from the VA roster of Operations Iraqi Freedom, Enduring Freedom, and New Dawn (OIF/ OEF/OND), provided by Defense Manpower Data Center-Contingency Tracking System Deployment File as part of the Women Veterans Cohort Study (31) . The roster includes information on sex, date of birth, race, and deployment start and end dates. For the current analyses, we included Veterans who were engaged in OIF/OEF/OND, and (1) whose end of last deployment was between September 2001 and July 2010, (2) whose first VA medical visit was between October 1, 2001 and January 1, 2009, and (3) who had at least 2 medical visits with a BP measurement during the period of observation after their last deployment end date. The initial sample thus included 274,679 Veterans. The institutional review boards at the parent organizations (Yale University, VA Connecticut Healthcare System) approved the cohort study on which the current data analyses are based.
Information on eligible medical visits, International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes recorded in the VA database and used to determine medical and psychiatric conditions, body mass index (BMI), Current Procedural Terminology (CPT) codes to determine the services delivered at each eligible medical visit, clinic BP readings, and medication prescriptions, were ascertained from the VA Corporate Data Warehouse. International Classification of Diseases, 9th Revision, Clinical Modification codes from outpatient visits were mapped to validated diagnostic groupings to determine a diagnosis of PTSD (ICD-9-CM 309.81), major depression (ICD-9-CM 296.2-3), and alcohol/substance use disorder (ICD-9-CM 291-292; 303-305) (32) . A Veteran was considered to have PTSD, depression, and/or substance use disorder if codes occurred on 2 or more outpatient visits, or one or more inpatient visit. This methodology has been used for the identification of psychiatric disorders in administrative data (33) , and for identification of HIV in Medicaid data (34) . In addition, incident hypertension was defined using information in the VA database, with 3 distinct events ascertained: (1) a new diagnosis of hypertension in the problem list (ICD-9-CM 401), and/or (2) a new prescription for antihypertensive medication, including angiotensinconverting enzyme inhibitors (e.g., lisinopril, captopril), angiotensin receptor blockers (e.g., losartan), beta-blockers (e.g., atenolol, propranolol), calcium channel blockers (e.g., amlodipine), and diuretics (e.g., hydrochlorothiazide); the antihypertensive medications clonidine and prazosin were not included in this classification, as they are also used for treating aspects of PTSD; and/or (3) an entry in the record of a clinic BP in the hypertensive range (≥140/90 mm Hg, systolic/diastolic).
Receipt of standard of care treatment for PTSD was defined as (1) CPT codes indicating at least 8 individual psychotherapy sessions of 50 minutes or longer duration (CPT 90834, 90837) over any consecutive 6 months during the period of observation, and/or (2) a prescription for selective serotonin reuptake inhibitor (SSRI) medications recorded in the VA database.
Blood pressure measurements that had implausible systolic values (<70 mm Hg or >240 mm Hg) or diastolic values (<35 mm Hg or >140 mm Hg) were removed (0.06% BP measures removed, leaving 274,659 veterans). If there were 2 or more BP recordings on the same day, the BP measurement with the lowest systolic value was retained. Veterans who before or on the day of first BP measurement (1) 
Statistical Analysis
Descriptive statistics were used to summarize the characteristics of the sample. We report overall group statistics, and by PTSD and treatment status ( Table 1 ). The prospective contribution of PTSD, of treatment, and of the interaction of these variables to risk for incident hypertension was tested using Cox proportional hazards regression. Time zero (baseline) was the time of the first available BP measurement for each veteran. We separately analyzed the time to the following 3 events: 1) earliest occurrence of hypertension diagnosis (event 1); 2) earliest occurrence of hypertension diagnosis and/or antihypertensive medication prescription (event 2); 3) earliest occurrence of hypertension diagnosis, and/or antihypertensive medication prescription, and/or BP measurement in the hypertensive range (event 3).
Veterans who did not experience any of these events were censored on the date of their last recorded BP measurement.
The main predictor of interest was PTSD status, which was treated as a binary time-dependent variable valued zero before PTSD diagnosis and 1 IQR,Interquartile Range; BMI = body mass index; BP = blood pressure; SBP = systolic blood pressure; DBP = diastolic blood pressure; SSRI = selective serotonin reuptake inhibitor.
* Events per 1,000 person years provides an index of the incidence of new events that happen over time and accommodates the variable length of follow-up per individual. It provides a metric for comparison between subgroups and event types within this sample, and a metric for comparison to other samples.
after diagnosis. Veterans who did not receive a PTSD diagnosis during the period of observation had the PTSD variable of zero throughout. The models also included a binary time-dependent variable for PTSD treatment, with value 1 after treatment was received (earliest 6-month period with 8 or more individual psychotherapy CPT codes or first SSRI prescription) and value zero otherwise. Other predictors included in the regression analyses were sex, race/ethnicity (white, black, Hispanic, or other), age at baseline, baseline systolic/diastolic BP, baseline BMI (closest BMI within 90 days of baseline) and baseline smoking (indication in the VA database of positive smoking status within 180 days of baseline). Veterans endorsing both white and Hispanic were coded as Hispanic; veterans who endorsed both black and Hispanic were coded as black. We also adjusted for a diagnosis of major depression and of substance use disorder (alcohol or drug abuse), both as time-dependent variables valued zero before diagnosis and 1 after diagnosis. Furthermore, we anticipated that veterans with mental health disorders may have had higher use of medical services (such as primary care), which could lead to ascertainment bias if these Veterans had more frequent assessment of BP. Therefore, we additionally adjusted the models for a time-dependent covariate representing each Veteran's number of days with a BP measurement during 90-day intervals. We fitted models with main effects for all the variables described. We then investigated if the association of PTSD with hypertension depends on whether treatment was received by adding a PTSD by treatment interaction term to the models. To test for sex differences in this association, we further included the 2-and 3-way interactions of sex with PTSD and treatment. To simplify the interpretation of results, we removed interaction terms that were not statistically significant at the .05 level from the final models.
RESULTS
Study Sample
The final sample of 194,319 veterans was 85% male and 65% white, with a median age at baseline of 27. ; 32% were smokers. During the period of observation, 11% received a diagnosis of major depression, and 13% received a diagnosis of substance use/abuse disorder. Additionally, during the time of observation, 36% (n = 69,583) received a diagnosis of PTSD; 6% received psychotherapy (13% with PTSD, 1% without), and 35% received prescription for SSRI medication (74% with PTSD, 17% without). Because most veterans who received psychotherapy also received SSRI medication (81%), these were combined into a single "treatment" term for analyses (Table 1) .
PTSD and Incident Hypertension
Of the total sample, 10% received a diagnosis of hypertension (event 1, N = 19,420), with an additional 8% being prescribed an antihypertensive medication (event 2, cumulative, 17%; N = 33,030) and an additional 27% evidencing BP in the hypertensive range (event 3, cumulative, 45%; N = 87,450). In the Cox models with main effects only, PTSD was associated with a hazard ratio (HR) of 1.12 (95% CI, 1.08-1.17; p < .0001) for event 1, 1.30 (95% CI, 1.26-1.34; p < .0001) for event 2 (which by definition included event 1), and 1.27 (95% CI, 1.25-1.30; p < .0001) for experiencing event 3 (which by definition included events 1 and 2). In addition, treatment was associated with an HR of 1.18 (95% CI 1.14-1.23, p < .0001), 1.46 (95% CI, 1.42-1.51; p < .0001), and 1.32 (95% CI, 1.30-1.34; p < .0001) for events 1, 2, and 3, respectively.
In the Cox models that considered interactions of PTSD, treatment, and sex, the PTSD by treatment interaction was significant (p < .0001) for events 1, 2, and 3 (Table 2) , whereas the PTSD by sex interaction was significant only for event 3 (p = .010; Table 2 ). Among veterans with PTSD who did not receive treatment during the period of observation, the HR for the effect of PTSD on event 1 was 1.24 (95% CI, 1.17-1.31; p < .0001), whereas for those who In the Cox model for event 3, the HR associated with PTSD was significantly higher in women than in men. Table 2 presents, separately for males and females, the effect of PTSD on event 3 by treatment status. As was the case for events 1 and 2 in the full cohort, the effect of PTSD for event 3 was significantly lower among veterans who received PTSD treatment (HR,1.13; 95% CI, 1.10-1.16; p < .0001 for men; HR,1.21, 95% CI 1.15-1.27; p < .0001, for females) than among veterans who did not (HR,1.37; 95% CI, 1.33-1.40; p < .0001, for males; HR, 1.46; 95% CI, 1.39-1.54; p < .0001, for females).
DISCUSSION
In this nationally representative sample of almost 200,000 OIF/OEF/OND veterans who received care through the VA during the period of observation, a diagnosis of PTSD left untreated was associated with a 24% to 46% greater risk of incident hypertension. This finding held for both men and women veterans, with women showing a slightly higher risk for early BP elevation into the hypertensive range. The finding that women had a higher risk for early BP in the hypertensive range but not for receipt of an antihypertensive medication or a hypertension diagnosis may indicate that women are less likely to receive a hypertension diagnosis and/or antihypertensive medication than men even when their BP is in the hypertensive range, for example, even with this hypertensive BP, they did not receive medication or diagnosis. This finding is consistent with literature concerning other CVD risk factors (35) . The overall findings in a nationwide veteran cohort substantially extend beyond the prior research concerning PTSD and hypertension risk, which has largely been cross-sectional (15, 29) .
In the current study, we observed an overall hypertension incidence over a median of 2.4-year follow-up that ranged from 10% to 45%, depending on how hypertension was defined, all in a young sample (mean age, 27.9 years; IQR, 24.4-37.6 years). This incidence in a young group of individuals, observed soon after separation from military service, is alarming, occurring much earlier than typically observed in the general US population or Western societies (36, 37) , and much greater than reported in other studies of military veterans. For example, the Millennium Cohort Study of approximately 55,000 active duty and Reserve/ National Guard members reported a 33% increased odds (95% CI, 1.07-1.65) of self-reported hypertension at 3-year follow-up among individuals with multiple combat exposures versus those who were not deployed to conflict zones; however, the contribution specifically of psychiatric disorders such as PTSD, depression, and substance use was not ascertained (38) . Furthermore, self-reported hypertension was observed in only 6.1% of those with multiple combat exposures and 7.3% in those who were not deployed. Thus, the results of the present study indicate that efforts to reduce the long-term health impact of PTSD in military Veterans, and the associated costs in quality of life and health care dollars, may require very early surveillance, and the testing of treatment algorithms that involve lower thresholds for antihypertensive treatment.
The current report is also the first showing that treatment, a VA imperative (39) and here defined by SSRI prescription and/or receipt of individual psychotherapy, may affect PTSD-associated hypertension risk. This finding, whereas not previously reported, is more complicated, since as a main effect, treatment was associated with elevated hypertension risk, and indeed, the event rate per 1,000 person years was higher in the groups (with and without PTSD) that received treatment. In a previous follow-up of Australian Gulf War Veterans (40), it was reported that only current PTSD (e.g., at the time of the assessment) was associated with incident hypertension, in comparison to having a trauma history and no current PTSD. The authors concluded that veterans who no longer met criteria for PTSD presumably also did not continue to evidence the physiological dysregulation that characterizes this diagnosis. Theories that outline a causal path from PTSD to physical disease point to dysregulation in hypothalamic pituitary-adrenocortical and sympathetic-adrenal-medullary stress axes (41, 42) . Ongoing dysregulation in these pathways can disrupt regulation of BP, inflammation, and associated gene expression (43) . There may also be a concomitant down-regulation of vagal input to relevant processes, including regulation of both acute and chronic hemodynamics and inflammatory processes (44, 45) . The mitigation of PTSD by treatment-or the passage of time (46, 47) -may promote a return of these key biological processes to a more normal state, and thus a reduction of incident hypertension risk. Longer-term follow-up of the OIF/ OEF/OND cohort will be required to ascertain whether a history of PTSD in remission truly normalizes incident hypertension risk or defines an additional at-risk group, when compared to individuals with no history of PTSD.
While the prospective finding in this nationally representative sample of OIF/OEF/OND Veterans seeking care through the VA of both increased incident hypertension risk attributable to PTSD and of PTSD-associated risk mitigation with treatment make important new contributions to the literature, the current report also has several limitations. The findings rely on administrative data, thus the accuracy of some data, particularly BP measurements, may be questioned. Clinic BP measurement within VA is largely accomplished with the use of automated devices, with the patient seated, and the displayed BP entered in the EMR. These BPs are then used for clinical decision making. While we cannot confirm the approach used in every VHA facility from which data were drawn, the consistency of finding for all 3 defined outcomes-diagnosis, medication prescription, and/or BP elevated above the hypertensive range-tempers this concern. There may also be misclassification in the study measures for PTSD and for hypertension, along with measures of other veteran characteristics. Yet, the findings hold when hypertension is defined by diagnosis-an ICD-9 code on which billing is based-and/or prescription of antihypertensive medication, which also has billing implications. We have adjusted the analysis for known demographic, clinical, lifestyle, and access-related factors that were assessed and could potentially bias the association between PTSD and hypertension.
There may also be selection/ascertainment bias related to seeking VA care based on PTSD symptoms. Despite analytic control, the possibility of ascertainment bias or residual confounding from known or unknown factors remains. It may also be that Veterans with more severe PTSD and/or hypertensive symptoms come to VA for care, and thus the findings may not generalize to veterans who receive care elsewhere, or to members of the general population that experience trauma and subsequently develop PTSD. Yet, approximately 50% of OIF/OEF/OND Veterans have registered with the VA, and of these, over 80% have at least 1 medical visit on record. Thus, a large proportion is represented by these data. Finally, it is not possible to ascertain the extent to which the diagnosis of PTSD is based on a brief screen, self-report instrument, or diagnostic interview. Thus, the observed incidence may be higher-or lowerthan would be determined with proper assessment.
The findings regarding treatment-SSRI medication and/or psychotherapy-are also conflicting, showing a lowering of PTSD-associated hypertension risk, yet also showing an independent elevation of risk as a main effect, and a higher event rate for those receiving treatment. These observational data were not comprehensive, in that PTSD symptom severity was not available, and thus those receiving treatment may have had more severe PTSD and thus the highest risk for incident hypertension, for example, PTSD treatment as defined here may have been a proxy for severity. In addition, key lifestyle factors (48, 49) such as physical activity, diet, and sleep, each known to increase hypertension risk, were not available. Furthermore, 17% of the overall sample without PTSD received treatment as defined by the study--almost all SSRI medication, perhaps for chronic pain-and there is evidence of an association between use of SSRI medications and hypertension (50) , and of chronic pain and hypertension (51) . The effect of treatment on PTSD-associated hypertension risk was not specifically tested in a randomized clinical trial, and the definition of treatment was imprecise in that we were unable to determine whether individual psychotherapy received was evidence based for PTSD (50) , or whether prescription of SSRI medication was for PTSD versus other factors such as comorbid depression. The question of whether PTSD treatment affects PTSD-associated hypertension risk will be critical to ascertain, so as to inform best approaches for CVD risk reduction among individuals with PTSD.
Given the VA imperative to provide PTSD treatment (52), it may not be possible to conduct a randomized clinical trial testing the effect of PTSD treatment on the associated incident hypertension risk, as this would entail withholding PTSD treatment for a period sufficient for new onset hypertension to be observed. A clinical trial that compares 2 different forms of PTSD therapy, for example, pharmacotherapy versus exposure therapy or cognitive reprocessing therapy, using variables such as daytime and night time average ambulatory BP, BP reactivity observed under controlled conditions during exposure to stressful tasks and/or PTSD relevant stimuli, and BP elevations during exposure to ecological stressors observed during ambulatory monitoring (53, 54) , may provide useful surrogate end points for such a trial.
CONCLUSIONS
We observed a 24% to 46% greater risk for incident hypertension associated with untreated PTSD in a large nationally representative sample of almost 200,000 veterans of OIF/OEF/OND military conflicts. This PTSD-associated risk was substantially lower among those veterans who received PTSD treatment, although these findings were somewhat conflicting. Therefore, the effect of PTSD treatment on subsequent hypertension risk should be studied in randomized clinical trials using surrogate end points (e.g., ambulatory BP), that would provide for more immediate effects that do not entail withholding of treatment. Furthermore, efforts to reduce the long-term health impact of PTSD and the associated costs in health care dollars may require early surveillance and the testing of treatment algorithms involving lower thresholds for antihypertensive treatment.
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